Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Rachel S. Dankner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6454-6000; OpenAlex author ID A5035913055. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
2
Papers, trials and grants by year

2012: 1 trial · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. Co-author DOI 10.1001/jamanetworkopen.2023.50408↗
  2. Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. Co-author DOI 10.1002/dmrr.3018↗

Trials 1

  1. Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort Principal investigator NCT02072902↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laurence S. Freedman · 2 shared papers, 2018–2024 · strength 0.38
  2. Lital Keinan‐Boker · 1 shared paper, 2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.